Results 121 to 130 of about 3,001 (186)

Identification of 20(S)-Ginsenoside Rh2 as a Potential EGFR Tyrosine Kinase Inhibitor. [PDF]

Oxid Med Cell Longev, 2022
Liang Y, Zhao J, Zou H, Zhang J, Zhang T.   +4 more
europepmc   +1 more source

Ginsenoside Rh2 attenuates the progression of non-small cell lung cancer by sponging miR-28-5p/STK4 axis and inactivating Wnt/β-catenin signaling. [PDF]

Cancer Med, 2023
Ma J, Zhao D, Yu D, Song W, Yang X, Yin H, Yin H.   +6 more
europepmc   +1 more source

Ginsenoside Rh2-Liposome Potentiate Vaccine Immunity through Enhanced MHC‑I Presentation. [PDF]

ACS Omega
Nie Q, Chen Z, Gong W, Cao W, Wang X, Liu Y, Zhang S, Yang Y, Meng Z.   +8 more
europepmc   +1 more source

Ginsenoside Rh2- functionalized liposomes enhanced BRD4-PROTAC delivery and antitumor efficacy <i>via</i> improved tumor targeting and ECM remodeling. [PDF]

Mater Today Bio
Wen L, Rao J, Chen J, Li F, Chen X, Guo S, Cui B, Qiu C, Chen W.   +8 more
europepmc   +1 more source

Structure Modification of Ginsenoside Rh₂ and Cytostatic Activity on Cancer Cells. [PDF]

ACS Omega, 2023
Liang J, Tang X, Wan S, Guo J, Zhao P, Lu L.   +5 more
europepmc   +1 more source

Ginsenoside Rh2 Induces HeLa Apoptosis through Upregulating Endoplasmic Reticulum Stress-Related and Downstream Apoptotic Gene Expression. [PDF]

Molecules, 2022
Liu Y, Wang X, Qiao J, Wang J, Jiang L, Wang C, Yu S, Zhang P, Zhao D, Fan M, Liu M.   +10 more
europepmc   +1 more source

Ginsenoside Rh2 as a novel PIN1 inhibitor disrupting the cancer stem cell-like phenotype in non-small cell lung cancer. [PDF]

J Transl Med
Liu X, Mao Z, Yang J, Zhu Q, Dong X, Huang G, Shen X, Zhang L, Yang H.   +8 more
europepmc   +1 more source

Ginsenoside Rh2 repressed the progression of prostate cancer through the mitochondrial damage induced by mitophagy and ferroptosis. [PDF]

Front Oncol
He Z, Shi J, Zhu B, Tian Z, Zhang Z, Zhang C.   +5 more
europepmc   +1 more source

Ginsenoside Rh2 Suppresses Metastasis and Growth of Colon Cancer via miR-491. [PDF]

J Oncol, 2021
Wei W, Guo Q, Guo C, Cui X, Ma X, Shen X, Luo Y.   +6 more
europepmc   +1 more source

Ginsenoside Rh2 targets SIRT1-mediated deacetylation to modulate ERα/AR balance and overcome endocrine therapy resistance in prostate cancer using 3D organoid models. [PDF]

Cell Biol Toxicol
Chen X, Luo W, Ren Y, Mou Z, Xu C, Hu J, Hu M, Jiang H.   +7 more
europepmc   +1 more source